Clinical Trials Directory

Trials / Terminated

TerminatedNCT02290574

Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial

Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Samsung Medical Center · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The investigators start this prospective study to evaluate the efficacy of laparoscopic total mesorectal excision after concurrent chemo-radiation therapy with hyperthermia in locally advanced rectal cancer.

Detailed description

The current standard treatment of locally advanced rectal cancer is neoadjuvant concurrent chemo-radiation therapy (CCRT) followed by total mesorectal excision (TME). Recently, laparoscopic surgery is getting substitute open surgery based on the advantages of early recovery, short admission, less pain, less blood loss, and little scar without compromising oncologic outcomes. It is reported that hyperthermia is effective in synthetic (S) phase, Low oxgen pressure, acidic, and low perfusion site which are known as radio-resistant. Because of these characteristics, it considered as the most valuable radiosensitizer in cancer treatment, theoretically. Furthermore, mild hyperthermia (41 to 41.5 ºC) can promote tumor reoxygenation. Based on those background, the investigators start this prospective study to evaluate the efficacy of laparoscopic TME after CCRT with hyperthermia in locally advanced rectal cancer.

Conditions

Interventions

TypeNameDescription
RADIATIONHyperthermia with concurrent chemo-radiation therapy

Timeline

Start date
2014-11-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2014-11-14
Last updated
2019-11-01
Results posted
2019-11-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02290574. Inclusion in this directory is not an endorsement.